Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

BACKGROUND: EGFR-mutant non-small cell lung cancer (NSCLC) is prone to leptomeningeal metastasis (LM) after Tyrosine kinase inhibitors (TKIs) treatment. Our previous study suggested that osimertinib plus bevacizumab was safe and effective in LM from EGFR-mutant NSCLC. This study aimed to compare the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Yali, Cai, Jing, Xu, Peng, Xiong, Le, Lu, Zhiqin, Zeng, Zhimin, Liu, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919569/
https://www.ncbi.nlm.nih.gov/pubmed/35287683
http://dx.doi.org/10.1186/s12967-022-03331-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919569/
https://www.ncbi.nlm.nih.gov/pubmed/35287683
http://dx.doi.org/10.1186/s12967-022-03331-9

Ejemplares similares